10-year study at UCL finds short chemotherapy course before standard treatment reduces cervical cancer deaths by 40% and recurrence risk by 35% over 5 years.

A study by University College London reveals that a short course of chemotherapy before standard treatment can reduce cervical cancer deaths by 40% and recurrence risk by 35% over five years. Conducted over ten years with 500 patients from multiple countries, the Interlace trial suggests this new regimen could be easily implemented and calls for its adoption in healthcare systems globally. The findings were published in The Lancet.

October 14, 2024
36 Articles